Clinical Trials Directory

Trials / Conditions / Metastatic Esophageal Squamous Cell Carcinoma

Metastatic Esophageal Squamous Cell Carcinoma

13 registered clinical trials studyying Metastatic Esophageal Squamous Cell Carcinoma — 4 currently recruiting.

StatusTrialSponsorPhase
RecruitingComparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected
NCT06265285
Mayo ClinicPhase 2
RecruitingSintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
NCT06138028
Qingdao Central HospitalPhase 2 / Phase 3
RecruitingA Study of IO Plus Radiotherapy in Patients With Advanced ESCC.
NCT05760391
Fudan UniversityN/A
RecruitingRadiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
NCT05978193
Shanghai Chest HospitalPhase 2
UnknownAK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC
NCT05522894
Chinese Academy of Medical SciencesPhase 2
UnknownConcurrent Chemoradiotherapy for Stage IVB Esophageal Squamous Cell Carcinoma（EC-CRT-003）
NCT05512520
Sun Yat-sen UniversityPhase 2
CompletedReal-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.
NCT05142709
Fudan University—
Active Not RecruitingEfficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participan
NCT04949256
Merck Sharp & Dohme LLCPhase 3
Active Not RecruitingTesting the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Eso
NCT04460937
National Cancer Institute (NCI)Phase 1
UnknownThe Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma
NCT03800953
National Taiwan University HospitalPhase 2
CompletedReal-world Experience of ICIs Plus Chemotherapy With or Without Radiotherapy for Advanced ESCC.
NCT06190652
Tianjin Medical University Cancer Institute and Hospital—
CompletedPrognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
NCT01472419
Samsung Medical Center—
Active Not RecruitingPaclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal
NCT01142388
National Cancer Institute (NCI)Phase 2